Senti Biosciences Reports Increased Losses Amid Strategic Moves

Senti Biosciences, Inc. ( (SNTI) ) has released its Q2 earnings. Here is a breakdown of the information Senti Biosciences, Inc. presented to its investors.

Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary gene circuit platform technologies, primarily targeting incurable diseases. In its latest earnings report for the quarter ending June 30, 2025, Senti Biosciences reported a net loss of $14.7 million, reflecting an increase from the $11.2 million loss in the same period last year. The company’s operating expenses rose due to increased research and development costs and general administrative expenses. Despite the losses, Senti Biosciences has made strategic moves, including a private placement that raised $35.2 million and the conversion of Series A redeemable convertible preferred stock into common stock. The company also continues to leverage its GeneFab-related transactions for financial and operational benefits. Looking ahead, Senti Biosciences remains focused on advancing its clinical trials and research activities, although it acknowledges the need for additional capital to sustain operations and achieve its long-term objectives.